Latest Conference Coverage

Bill Roth, general manager and managing partner of IntegriChain’s consulting business, previews his new six-part series by outlining how rising payer fragmentation, divergent cash and insurance models, and supply-chain constraints are reshaping brand strategy.

In a discussion on global trade disruption, Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, explains why pharmaceutical manufacturers must move beyond broad assumptions about tariffs and instead assess trade risk at the individual product level.

Cheryl Allen, BS Pharm, MBA, founding partner, highlights the coming year's focus on navigating an evolving regulatory landscape, while leveraging technology to track the pharmaceutical pipeline, assess analogs, and modernize distribution strategies.

A session explores how manufacturers can refine GTN strategy, strengthen pricing governance, and navigate increasingly complex distribution-channel economics, while maintaining both commercial performance and patient affordability.

In a wide-ranging keynote on disruption across pharmaceutical channels, Bill Roth, general manager and managing partner of IntegriChain’s consulting business, outlines why 2025 marks the beginning of a profound regulatory and commercial transformation—from sweeping policy shifts and accelerating WAC reductions to new debates on direct-to-patient strategies and looming instability in medical benefit reimbursement.

BioCare's Ryan Cort outlines the pharmaceutical industry's "unprecedented sea change," driven by over $400 billion in anticipated revenue loss from generics and biosimilars losing exclusivity.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, hopes to use the conference to explore how manufacturers can build the talent and support structures required to keep the US drug supply safe and accessible.

Jay McHarg, CEO of AeroSafe Global, reacts to the next generation of pharma delivery using innovations such as reusable packaging, integrated delivery systems, and real-time delivery intelligence.

Jay McHarg, CEO of AeroSafe Global, explains how a Targeted Risk Improvement Program improves resilience, reduces costs, and strengthens sustainability across the supply chain.

Hear how “delivery intelligence” is transforming the last mile of pharmaceutical logistics from Jay McHarg, CEO of AeroSafe Global.

As the FDA ends its phased exemption period for most trading partners, Two Labs’ Michael Rowe warns that DSCSA compliance is entering a far more complex era—one shaped by real-time traceability, digital record requirements, and a transition to a 12-digit NDC.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses how the convergence of patient access services with traditional distribution models is setting the stage for medically integrated dispensing to expand beyond oncology.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, highlights how two decades of commercial trade and distribution have transformed the channel from a primarily supply-chain-focused function into a more integrated discipline.

Subject matter experts from Cencora and FuzeRx explore how modern commercialization models, digital-first pharmacy solutions, and closer provider partnerships are reshaping patient access and adherence across today’s complex therapeutic landscape.

Commercialization expert Bill Roth outlines the critical need for "adaptive capacity," detailing how accelerating government regulation and massive patent cliffs are forcing a complete overhaul of commercial strategies across various markets.

At LogiPharma USA, industry leaders from Tive, McKesson, and the broader healthcare logistics community discussed the sector’s transition from passive monitoring to real-time control, the growing influence of advanced therapies, and the importance of diversity and innovation in shaping the future of pharma supply chains.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, shares that as DSCSA traceability requirements take full effect, distributors and trading partners are preparing for long-term gains in supply chain security, recall efficiency, and counterfeit prevention.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, describes how FDA officials are signaling a balanced enforcement approach when it comes to DSCSA enforcement, expecting compliance efforts and documentation, but also recognizing that perfection will take time.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, details that after a year of steady progress, manufacturers and distributors report over 97% data accuracy under DSCSA traceability requirements, marking a major milestone in supply chain interoperability and signaling confidence ahead of the November compliance deadline.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, describes how at this year’s seminar, attendees emphasized pragmatic approaches to achieving full compliance while anticipating upcoming FDA rules that could reshape wholesale and 3PL licensure standards across the pharma supply chain.

Krenar Komoni, founder and CEO of Tive, predicts that AI-driven automation and its accelerating impact on pharmaceutical supply chains will remain a headline topic at LogiPharma USA, as the industry faces growing pressure to innovate while balancing strict regulatory requirements.

Krenar Komoni, founder and CEO of Tive, highlights the transition in pharma from passive to real-time temperature control, noting delays in technology adoption but emphasizing how AI and automation will soon drive cost savings, improved quality, and stronger customer experience.

Ammie McAsey, SVP of Supply Chain Operations, McKesson, explains the critical role of real-time visibility, digital tools, and cold chain innovation in ensuring product quality, reducing disruptions, and strengthening patient care.

Krenar Komoni, founder and CEO of Tive, explains how the pharmaceutical industry’s transition from passive to real-time temperature control creates short-term challenges but will ultimately enable AI-driven automation, lower costs, higher quality, and better customer experiences.

As precision medicine reshapes drug distribution, Ammie McAsey, SVP of Supply Chain Operations, McKesson, highlights the need for deeper investments in technology, temperature control, and end-to-end visibility to ensure quality and patient safety in advanced therapy supply chains.

In a recent panel discussion, Krenar Komoni, founder and CEO of Tive, highlighted how combating rising supply chain theft requires a multi-layered, technology-driven security strategy.

Ammie McAsey, SVP of Supply Chain Operations, McKesson, emphasizes the critical role of collaboration, technology, and partnerships in ensuring advanced and specialty therapies reach patients safely and effectively.

Dave Malenfant, healthcare supply chain expert, reflects on LogiPharma USA’s 20-year evolution, noting its shift toward greater diversity and inclusion, particularly with more women entering the industry.